Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | OGT | O15294 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633263 | 0.93 | F10 (0.55) | F10MEN1KMT2AIKBKBCHUK | |
| SCHEMBL6578432 | 0.86 | F10 (0.46) | F10MEN1KMT2ALSSALDH1A1 | |
| SCHEMBL5631650 | 0.80 | ALDH1A1 (0.56) | F10MEN1KMT2ATPSAB1ALDH1A1 | |
| SCHEMBL7118163 | 0.78 | F10 (0.44) | F10LSS | |
| SCHEMBL7124112 | 0.77 | F2 (0.46) | F10MEN1KMT2ALSSALDH1A1 | |
| SCHEMBL7120480 | 0.75 | KMT2A (0.47) | F10MEN1KMT2ALSSALDH1A1 | |
| SCHEMBL7112884 | 0.75 | SLC6A4 (0.46) | MEN1KMT2A | |
| SCHEMBL6576136 | 0.75 | CYP3A4 (0.47) | F10MEN1KMT2ALSSALDH1A1 | |
| SCHEMBL8112377 | 0.72 | TPSAB1 (0.61) | F10TPSAB1LSS | |
| SCHEMBL5632390 | 0.72 | ALDH1A1 (0.45) | F10MEN1KMT2AIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | claimed |
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | F2, SERPINC1, F11 | F10 8/4885MEN1 594/4885KMT2A 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.